CBT-I vs. Sleeping Pills: What the Research Says About Long-Term Insomnia Treatment
There’s a moment many people recognize. You’re at your GP’s office, you’ve mentioned the sleep again, and there’s a small hesitation before they sign the renewal. They don’t say anything. Neither do you. The prescription goes through, same as last time, and you leave with the quiet understanding that this was never meant to go on this long.
Zopiclone, lorazepam, clonazepam. The names vary. The situation rarely does.
This post isn’t about making you feel guilty for taking a sleep medication. It’s about what the research says when you compare sleeping pills to CBT-I over time, what Canadian prescribing guidelines actually recommend, and why the conversation about stopping is more hopeful than most people expect.
Your Doctor’s Guidelines Say Something You May Not Have Heard
In 2022, Health Canada updated its communications on zopiclone and other Z-drugs, reinforcing that these medications are approved for short-term use and carry risks including dependence, tolerance, and complex sleep behaviours. These aren’t fringe concerns flagged by worried patients. They’re the federal regulator’s position.
The Canadian Centre on Substance Use and Addiction is more direct: benzodiazepines and Z-drugs are among the most commonly misused prescription medications in Canada, and long-term use for insomnia is not considered best practice by any major clinical body.
The Canadian Sleep Society names CBT-I as the first-line treatment for chronic insomnia, not as a preference, but as the recommendation supported by the weight of the evidence. This isn’t a niche position. The American College of Physicians reached the same conclusion independently in 2016. The consensus, internationally, is unusually clear for medicine: for chronic insomnia, start with CBT-I.
Most people who’ve been on a sleep medication for more than a few months were never told this.
What the Head-to-Head Research Shows
The landmark comparison was published in 1999 by Charles Morin and colleagues, and has been replicated many times since. In that randomized controlled trial, participants with chronic insomnia were assigned to CBT-I alone, medication alone, a combination of both, or placebo. At the end of treatment, all active conditions outperformed placebo. CBT-I and medication looked roughly comparable.
Then came the follow-up, at six months and two years.
Medication gains eroded. CBT-I gains held. In a 2009 study by the same group, participants who had completed CBT-I continued to improve after treatment ended. The people who had relied on medication during that same period had not maintained the same ground.
This is the finding that matters most: one rents you sleep. The other teaches your nervous system to generate it.
CADTH, the Canadian Agency for Drugs and Technologies in Health, reached a similar conclusion in its comparative review: CBT-I produces durable improvements in sleep onset latency, wake after sleep onset, and overall sleep quality that pharmacotherapy does not replicate over time.
It’s worth being specific about what “durable” means here. At two-year follow-up in the Morin studies, participants who had completed CBT-I were sleeping better than they had at the end of active treatment. The skills generalized. When a bad week arrived (stress, illness, a disrupted schedule) they had tools that bent without breaking. The people in the medication arm did not have the same cushion. They had managed the symptom. The vulnerability remained.
Why Pills Feel Like the Reasonable Choice
None of this means sleep medications are without value, or that the people taking them made a bad decision. When your GP prescribed zopiclone at the end of a difficult appointment, they were responding to real distress with the tool immediately available.
The problem is structural. CBT-I requires time, a trained clinician, and a few weeks of treatment that can feel worse before it gets better. A prescription takes three minutes and works the same night. In a healthcare system that rewards throughput over outcomes, the path of least resistance and the path of best evidence diverge.
What the research also shows is that the combination approach, medication plus CBT-I, doesn’t outperform CBT-I alone at long-term follow-up. Adding a pill to a behavioural program doesn’t appear to make the behavioural program work better. If anything, it may complicate it, by giving the nervous system an alternative explanation for why sleep happened on a given night.
Jade Wu, a behavioral sleep medicine specialist, describes this as the PRN paradox: when sleep medication is prescribed “as needed,” it puts the patient in the position of deciding, at bedtime, whether tonight qualifies as a bad enough night to warrant the pill. That decision-making process is itself a form of sleep effort. It activates the same arousal system that’s driving the insomnia. The pill solves a problem the decision to take it just made worse.
What a Supervised Taper With CBT-I Looks Like
Before anything else: medication changes require your prescribing physician’s involvement. Benzodiazepines in particular carry withdrawal risks that are not trivial, and should never be stopped abruptly without medical supervision. Zopiclone tapers are generally more manageable but still benefit from a structured plan made with your GP.
What the evidence supports, and what I work through with clients, is a concurrent approach: begin CBT-I while initiating a gradual, predetermined taper schedule. The research on timing suggests that starting CBT-I before or alongside the taper, rather than after it’s complete, produces better outcomes. The behavioral work gives you something to stand on when the medication is no longer there.
The taper schedule matters more than most people expect. Research on zopiclone withdrawal suggests that irregular use, taking the pill on bad nights and skipping on better ones, actually perpetuates the dependence it’s trying to address. A fixed, written schedule that reduces the dose incrementally over several weeks tends to produce less rebound insomnia than ad hoc use, even if the ad hoc use is infrequent.
The reason is psychological as much as physiological. When the schedule is predetermined, you’re not negotiating with yourself at 11pm about whether tonight counts. That decision is already made. The cognitive weight of the pill shrinks. What was a nightly referendum on your sleep becomes a simple instruction you follow, and then eventually stop following.
Most tapers move through stages: lower the dose on a few predetermined nights first, then across all nights, then extend the gaps until you’re no longer taking it. The pace depends on how long you’ve been on the medication, the dose, and your individual response. Your GP sets the schedule. A CBT-I therapist helps you manage what happens to your sleep while it’s in progress.
In practice, the first week or two of a concurrent taper and CBT-I program is often the hardest. Sleep can worsen before it improves. This is expected, documented, and temporary. The technical term is rebound insomnia, and it happens because the nervous system, after being chemically suppressed for months or years, takes some time to recalibrate. Understanding that this is a phase, not a failure, changes how people move through it. People who push through this window tend to come out the other side sleeping in a way that feels qualitatively different from medicated sleep: less groggy, more consolidated, and not contingent on having something in the medicine cabinet.
Sleep You Built
Medicated sleep is borrowed. It happens because a molecule is suppressing the arousal that’s preventing it. When the molecule is gone, the arousal returns. Nothing about the underlying insomnia has changed.
CBT-I sleep is earned sleep. It happens because the physiological conditions for sleep have been rebuilt: a consolidated sleep drive, a bedroom that no longer registers as a threat, a nervous system that’s stopped treating wakefulness as an emergency. These changes persist because they’re structural.
That’s not an argument for suffering through bad nights indefinitely. Medication has a legitimate role in acute insomnia, in crisis periods, and in situations where the alternative is dangerous sleeplessness. But for chronic insomnia that’s been running for months or years, the research is consistent: the best long-term outcomes come from addressing what’s driving the insomnia, not from continuing to suppress it.
If you’re somewhere in the middle, still on the medication, not sleeping well on it, not sure what the path forward looks like, that’s exactly the conversation a CBT-I consultation is designed to start. You can book a free call here to talk through where you are and whether CBT-I makes sense for your situation.
You don’t have to figure out the taper first. You can figure it out together.
